abstract |
The invention relates to a pharmaceutical composition comprising interfering RNAs (iRNAs) silencing IL-1β, IL-6, IL-18 and/or IL-17, in combination with a lipopolyamine, and to the use of the composition for preventing or treating an inflammatory disorder such as rheumatoid arthritis. |